HONG KONG – South Korea is the third biggest pharmaceutical market in Asia following China and Japan. Even though it accounts for 1.8% of the global pharmaceutical market, the country aims to launch at least two blockbuster drugs by 2030. Backed by massive support from the government, Korea's biopharmaceutical industry is focusing on R&D, production and out-licensing to make high-value new drugs.